All lobbying filings

TIBER CREEK GROUP

Lobbying for MERCK & CO., INC · Prescription medicines, vaccines, and biologic therapies

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 19, 2026

Official filing document

Bills named in this filing 2

HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 8857
Next GEN Act of 2026

Lobbying activity 3

Medicare/Medicaid

Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.

Trade (domestic/foreign)

Issues related to intellectual property protections.

Health Issues

Issues related to immunization policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.